Clinical Trial Update: Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) [Phase 2]

View source ↗

Summary

The HepSTAR Phase 2 trial comparing TACE alone versus TACE plus SABR for BCLC stage B hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Liver Neoplasms, Hepatocellular Cancer | Phase 2 | Status: TERMINATED